Skip to main content
. 2015 May 13;35(19):7414–7427. doi: 10.1523/JNEUROSCI.4079-14.2015

Figure 4.

Figure 4.

Blocking NKCC1 activation with bumetanide or furosemide prevented neurite outgrowth of NF200+ (myelinated) neurons. A, B, D, E, G, H, J, K, Images of DRG explants labeled with NF200 (A, B, G, H) or β-Tub (D, E, J, K). C, F, I, L, Bumetanide or furosemide administration reduced neurite outgrowth as shown by the decrease in the number of intersections in NF200+-labeled explants (***p < 0.005 and *p < 0.05, DMSO (vehicle) vs bumetanide 200 μm; **p < 0.01, DMSO vs furosemide 50 μm; ####p < 0.0001 and ###p < 0.001, DMSO vs furosemide 100 μm; ****p < 0.0001 and **p < 0.01, DMSO vs furosemide 200 μm; C and I, respectively), but not in those labeled with β-Tub (F and L, respectively). M, N, Plots of the neurites that were β-Tub+ but NF200−, corresponding to unmyelinated fibers (****p < 0.001, ***p < 0.005, *p < 0.05, vehicle vs bumetanide 200 μm). Scale bar, 500 μm. Data are presented as the mean ± SEM.

HHS Vulnerability Disclosure